A comprehensive review of dermatomyositis treatments - from rediscovered classics to promising horizons

References

• Selva-O’Callaghan A, Pinal-Fernandez I, Trallero-Araguas E, et al. Classification and management of adult inflammatory myopathies. Lancet Neurol. 2018 Sep;17(9):816–828. doi: 10.1016/S1474-4422(18)30254-0
   PubMed Web of Science ®Google Scholar
• Casal-Dominguez M, Pinal-Fernández I, Mammen AL. Utility of myositis-specific autoantibodies for treatment selection in myositis. Curr Treat Options Rheumatology. 2022 Dec 01;8(4):105–116.
   Google Scholar
• Casal-Dominguez M, Pinal-Fernandez I, Pak K, et al. Performance of the 2017 European alliance of associations for rheumatology/American college of rheumatology classification criteria for idiopathic inflammatory myopathies in patients with myositis-specific autoantibodies. Arthritis & Rheumat. 2022 Mar;74(3):508–517. doi: 10.1002/art.41964
   PubMed Web of Science ®Google Scholar
• Van Gompel E, Demirdal D, Fernandes-Cerqueira C, et al. Autoantibodies against the melanoma differentiation-associated protein 5 in patients with dermatomyositis target the helicase domains. Rheumatology. 2023. doi: 10.1093/rheumatology/kead400
   PubMedGoogle Scholar
• Pinal-Fernandez I, Mecoli CA, Casal-Dominguez M, et al. More prominent muscle involvement in patients with dermatomyositis with anti-Mi2 autoantibodies. Neurology. 2019 Nov 5;93(19):e1768–e1777. doi: 10.1212/WNL.0000000000008443
   PubMedGoogle Scholar
• Albayda J, Pinal-Fernandez I, Huang W, et al. Antinuclear matrix protein 2 autoantibodies and edema, muscle disease, and Malignancy risk in dermatomyositis patients. Arthritis Care Res (Hoboken). 2017 Nov;69(11):1771–1776. doi: 10.1002/acr.23188
   PubMed Web of Science ®Google Scholar
• Selva-O’Callaghan A, Romero-Bueno F, Trallero-Araguas E, et al. Pharmacologic treatment of anti-MDA5 rapidly progressive interstitial lung disease. Curr Treatm Opt Rheumatol. 2021;7(4):319–333. doi: 10.1007/s40674-021-00186-x
   PubMedGoogle Scholar
• Pinal-Fernandez I, Ferrer-Fabregas B, Trallero-Araguas E, et al. Tumour TIF1 mutations and loss of heterozygosity related to cancer-associated myositis. Rheumatology (Oxford). 2018 Feb 1;57(2):388–396. doi: 10.1093/rheumatology/kex413
   PubMed Web of Science ®Google Scholar
• Cordel N, Derambure C, Coutant S, et al. TRIM33 gene somatic mutations identified by next generation sequencing in neoplasms of patients with anti-TIF1gamma positive cancer-associated dermatomyositis. Rheumatology (Oxford). 2021 Dec 1;60(12):5863–5867. doi: 10.1093/rheumatology/keab260
   PubMed Web of Science ®Google Scholar
• Hosono Y, Sie B, Pinal-Fernandez I, et al. Coexisting autoantibodies against transcription factor Sp4 are associated with decreased cancer risk in patients with dermatomyositis with anti-TIF1gamma autoantibodies. Ann Rheum Dis. 2023 Feb;82(2):246–252. doi: 10.1136/ard-2022-222441
   PubMed Web of Science ®Google Scholar
• Fiorentino D, Mecoli CA, Igusa T, et al. Association of anti-CCAR1 autoantibodies with decreased cancer risk relative to the General population in patients with anti-transcriptional intermediary factor 1γ-positive dermatomyositis. Arthritis & Rheumat. 2023 Jul;75(7):1238–1245. doi: 10.1002/art.42474
   PubMed Web of Science ®Google Scholar
• Sherman MA, Pak K, Pinal-Fernandez I, et al. Autoantibodies recognizing specificity protein 4 co-occur with anti–transcription intermediary factor 1 and are associated with distinct clinical features and immunogenetic risk factors in juvenile myositis. Arthritis & rheumat. 2023 Mar 30;75:1668–1677. doi: 10.1002/art.42512
   PubMed Web of Science ®Google Scholar
• Greenberg SA, Pinkus JL, Pinkus GS, et al. Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol. 2005 May;57(5):664–678. doi: 10.1002/ana.20464
   PubMed Web of Science ®Google Scholar
• Pinal-Fernandez I, Casal-Dominguez M, Derfoul A, et al. Identification of distinctive interferon gene signatures in different types of myositis. Neurology. 2019 Sep 17;93(12):e1193–e1204. doi: 10.1212/WNL.0000000000008128
   PubMed Web of Science ®Google Scholar
• Pinal-Fernandez I, Casal-Dominguez M, Derfoul A, et al. Machine learning algorithms reveal unique gene expression profiles in muscle biopsies from patients with different types of myositis. Ann Rheum Dis. 2020 Sep;79(9):1234–1242. doi: 10.1136/annrheumdis-2019-216599
   PubMed Web of Science ®Google Scholar
• Amici DR, Pinal-Fernandez I, Christopher-Stine L, et al. A network of core and subtype-specific gene expression programs in myositis. Acta Neuropathol. 2021 Nov;142(5):887–898. doi: 10.1007/s00401-021-02365-5
   PubMed Web of Science ®Google Scholar
• Pinal-Fernandez I, Mammen AL. Dermatomyositis etiopathogenesis: a rebel soldier in the muscle. Curr Opin Rheumatol. 2018 Nov;30(6):623–629. doi: 10.1097/BOR.0000000000000540
   PubMed Web of Science ®Google Scholar
• Pinal-Fernandez I, Greenberg SA. Type I interferons in dermatomyositis myoblasts: toxic effect and a potential autocrine loop. Neurology. 2022 May 24;98(21):869–870.
   PubMed Web of Science ®Google Scholar
• Pinal-Fernandez I, Milisenda JC, Pak K, et al. Transcriptional derepression of CHD4/NuRD-regulated genes in the muscle of patients with dermatomyositis and anti-Mi2 autoantibodies. Ann Rheumatic Dis. 2023;82:ard-2023–223873. doi: 10.1136/ard-2023-223873
   Web of Science ®Google Scholar
• Nozaki K, Pestronk A. High aldolase with normal creatine kinase in serum predicts a myopathy with perimysial pathology. J Neurol Neurosurg Psychiatry. 2009 Aug;80(8):904–908. doi: 10.1136/jnnp.2008.161448
   PubMed Web of Science ®Google Scholar
• Sontheimer RD. Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sine myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? J Am Acad Dermatol. 2002 Apr;46(4):626–636. doi: 10.1067/mjd.2002.120621
   PubMed Web of Science ®Google Scholar
• Labrador-Horrillo M, Martinez MA, Selva-O’Callaghan A, et al. Anti-MDA5 antibodies in a large Mediterranean population of adults with dermatomyositis. J Immunol Res. 2014;2014:290797. doi: 10.1155/2014/290797
   PubMed Web of Science ®Google Scholar
• Olivo Pallo PA, Hoff LS, Borges IBP, et al. Characterization of patients with dermatomyositis according to anti–melanoma differentiation-associated gene-5 autoantibodies in centers from 3 Latin American countries: a cohort study. JCR: J Clinic Rheumatol. 2022;28(2):e444–e448. doi: 10.1097/RHU.0000000000001756
   PubMed Web of Science ®Google Scholar
• Romero-Bueno F, Diaz Del Campo P, Trallero-Araguas E, et al. Recommendations for the treatment of anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated rapidly progressive interstitial lung disease. Semin Arthritis Rheum. 2020 Aug;50(4):776–790. doi: 10.1016/j.semarthrit.2020.03.007
   PubMed Web of Science ®Google Scholar
• Chen Z, Wang X, Ye S. Tofacitinib in amyopathic dermatomyositis-associated interstitial lung disease. N Engl J Med. 2019 Jul 18;381(3):291–293. doi: 10.1056/NEJMc1900045
   PubMed Web of Science ®Google Scholar
• Shirani Z, Kucenic MJ, Carroll CL, et al. Pruritus in adult dermatomyositis. Clin Exp Dermatol. 2004 May;29(3):273–276. doi: 10.1111/j.1365-2230.2004.01510.x
   PubMed Web of Science ®Google Scholar
• Kim HJ, Zeidi M, Bonciani D, et al. Itch in dermatomyositis: the role of increased skin interleukin-31. Br J Dermatol. 2018 Sep;179(3):669–678. doi: 10.1111/bjd.16498
   PubMed Web of Science ®Google Scholar
• Pinal-Fernandez I, Fonollosa-Pla V, Selva-O’Callaghan A. Improvement of the nailfold capillaroscopy after immunosuppressive treatment in polymyositis. QJM. 2016 Mar;109(3):205–206. doi: 10.1093/qjmed/hcv196
   PubMed Web of Science ®Google Scholar
• Fiorentino D, Chung L, Zwerner J, et al. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol. 2011 Jul;65(1):25–34. doi: 10.1016/j.jaad.2010.09.016
   PubMed Web of Science ®Google Scholar
• Bernet LL, Lewis MA, Rieger KE, et al. Ovoid palatal patch in dermatomyositis: a novel finding associated with anti-TIF1gamma (p155) antibodies. JAMA Dermatol. 2016 Sep 1;152(9):1049–1051. doi: 10.1001/jamadermatol.2016.1429
   PubMed Web of Science ®Google Scholar
• Dourmishev L, Meffert H, Piazena H. Dermatomyositis: comparative studies of cutaneous photosensitivity in lupus erythematosus and normal subjects. Photodermatol Photoimmunol Photomed. 2004 Oct;20(5):230–234. doi: 10.1111/j.1600-0781.2004.00115.x
   PubMed Web of Science ®Google Scholar
• Quain RD, Werth VP. Management of cutaneous dermatomyositis: current therapeutic options. Am J Clin Dermatol. 2006;7(6):341–351. doi: 10.2165/00128071-200607060-00002
   PubMed Web of Science ®Google Scholar
• Sontheimer RD. The management of dermatomyositis: current treatment options. Expert Opin Pharmacother. 2004 May;5(5):1083–1099. doi: 10.1517/14656566.5.5.1083
   PubMed Web of Science ®Google Scholar
• Yoshimasu T, Ohtani T, Sakamoto T, et al. Topical FK506 (tacrolimus) therapy for facial erythematous lesions of cutaneous lupus erythematosus and dermatomyositis. Eur J Dermatol. 2002 Jan;12(1):50–52.
   PubMed Web of Science ®Google Scholar
• Hollar CB, Jorizzo JL. Topical tacrolimus 0.1% ointment for refractory skin disease in dermatomyositis: a pilot study. J DermatolTreat. 2004 Jan;15(1):35–39. doi: 10.1080/09546630310018509
   Google Scholar
• García-Doval I, Cruces M. Topical tacrolimus in cutaneous lesions of dermatomyositis: lack of effect in side-by-side comparison in five patients. Dermatology. 2004;209(3):247–248. doi: 10.1159/000079903
   PubMed Web of Science ®Google Scholar
• Zhen C, Hou Y, Zhao B, et al. Efficacy and safety of rituximab treatment in patients with idiopathic inflammatory myopathies: a systematic review and meta-analysis. Front Immunol. 2022;13:1051609. doi: 10.3389/fimmu.2022.1051609
   PubMed Web of Science ®Google Scholar
• Wendel S, Venhoff N, Frye BC, et al. Successful treatment of extensive calcifications and acute pulmonary involvement in dermatomyositis with the Janus-kinase inhibitor tofacitinib - a report of two cases. J Autoimmun. 2019 Jun;100:131–136.
   PubMed Web of Science ®Google Scholar
• Shneyderman M, Ahlawat S, Christopher-Stine L, et al. Calcinosis in refractory dermatomyositis improves with tofacitinib monotherapy: a case series. Rheumatology (Oxford). 2021 Nov 3;60(11):e387–e388. doi: 10.1093/rheumatology/keab421
   PubMed Web of Science ®Google Scholar
• Gordon PA, Winer JB, Hoogendijk JE, et al. Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis. Cochrane Database Syst Rev. 2012 Aug;15(8):CD003643. doi: 10.1002/14651858.CD003643.pub4
   Google Scholar
• Drake LA, Dinehart SM, Farmer ER, et al. Guidelines of care for dermatomyositis. American Academy of Dermatology. J Am Acad Dermatol. 1996 May;34(5 Pt 1):824–829. doi: 10.1016/S0190-9622(96)90037-7
   PubMedGoogle Scholar
• Briemberg HR, Amato AA. Dermatomyositis and polymyositis. Curr Treat Options Neurol. 2003 Sep 01;5(5):349–356.
   PubMedGoogle Scholar
• Huapaya JA, Silhan L, Pinal-Fernandez I, et al. Long-term treatment with azathioprine and Mycophenolate mofetil for myositis-related interstitial lung disease. Chest. 2019 Nov;156(5):896–906. doi: 10.1016/j.chest.2019.05.023
   PubMed Web of Science ®Google Scholar
• Schiopu E, Phillips K, MacDonald PM, et al. Predictors of survival in a cohort of patients with polymyositis and dermatomyositis: effect of corticosteroids, methotrexate and azathioprine. Arthritis Res Ther. 2012 Jan 27;14(1):R22. doi: 10.1186/ar3704
   PubMed Web of Science ®Google Scholar
• Casal-Dominguez M, Pinal-Fernandez I, Huapaya J, et al. Efficacy and adverse effects of methotrexate compared with azathioprine in the antisynthetase syndrome. Clin Exp Rheumatol. 2019 Sep;37(5):858–861.
   PubMed Web of Science ®Google Scholar
• Pisoni CN, Cuadrado MJ, Khamashta MA, et al. Mycophenolate mofetil treatment in resistant myositis. Rheumatology (Oxford). 2007 Mar;46(3):516–518. doi: 10.1093/rheumatology/kel336
   PubMed Web of Science ®Google Scholar
• Rowin J, Amato AA, Deisher N, et al. Mycophenolate mofetil in dermatomyositis: is it safe? Neurology. 2006 Apr 25;66(8):1245–1247. doi: 10.1212/01.wnl.0000208416.32471.c0
   PubMed Web of Science ®Google Scholar
• Edge JC, Outland JD, Dempsey JR, et al. Mycophenolate mofetil as an effective corticosteroid-sparing therapy for recalcitrant dermatomyositis. Arch Dermatol. 2006 Jan;142(1):65–69. doi: 10.1001/archderm.142.1.65
   PubMed Web of Science ®Google Scholar
• Gelber AC, Nousari HC, Wigley FM. Mycophenolate mofetil in the treatment of severe skin manifestations of dermatomyositis: a series of 4 cases. J Rheumatol. 2000 Jun;27(6):1542–1545.
   PubMed Web of Science ®Google Scholar
• Tausche AK, Meurer M. Mycophenolate mofetil for Dermatomyositis. Dermatology. 2001;202(4):342–343. doi: 10.1159/000051674
   Web of Science ®Google Scholar
• Danieli MG, Calcabrini L, Calabrese V, et al. Intravenous immunoglobulin as add on treatment with mycophenolate mofetil in severe myositis. Autoimmun Rev. 2009 Dec;9(2):124–127. doi: 10.1016/j.autrev.2009.04.003
   PubMed Web of Science ®Google Scholar
• Rouster-Stevens KA, Morgan GA, Wang D, et al. Mycophenolate mofetil: a possible therapeutic agent for children with juvenile dermatomyositis. Arthritis Care Res (Hoboken). 2010 Oct;62(10):1446–1451. doi: 10.1002/acr.20269
   PubMed Web of Science ®Google Scholar
• Varnier GC, Consolaro A, Cheng IL, et al. Experience with the use of mycophenolate mofetil in juvenile idiopathic inflammatory myopathies. Rheumatology (Oxford). 2023 Feb 23;62(Si2):Si163–si169. doi: 10.1093/rheumatology/keac404
   PubMed Web of Science ®Google Scholar
• Saketkoo LA, Espinoza LR. Experience of mycophenolate mofetil in 10 patients with autoimmune-related interstitial lung disease demonstrates promising effects. Am J Med Sci. 2009 May;337(5):329–335. doi: 10.1097/MAJ.0b013e31818d094b
   PubMed Web of Science ®Google Scholar
• Swigris JJ, Olson AL, Fischer A, et al. Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. Chest. 2006 Jul;130(1):30–36. doi: 10.1016/S0012-3692(15)50949-5
   PubMed Web of Science ®Google Scholar
• Morganroth PA, Kreider ME, Werth VP. Mycophenolate mofetil for interstitial lung disease in dermatomyositis. Arthritis Care Res (Hoboken). 2010 Oct;62(10):1496–1501. doi: 10.1002/acr.20212
   PubMed Web of Science ®Google Scholar
• Zabel P, Leimenstoll G, Gross WL. Treatment of an acute dermatomyositis with cyclosporin a. Immun Infekt. 1984 Feb;12(1):41–42.
   PubMedGoogle Scholar
• Ejstrup L. Severe dermatomyositis treated with cyclosporin a. Ann Rheum Dis. 1986 Jul;45(7):612–613. doi: 10.1136/ard.45.7.612-b
   PubMed Web of Science ®Google Scholar
• Heckmatt J, Hasson N, Saunders C, et al. Cyclosporin in juvenile dermatomyositis. Lancet. 1989 May 13;1(8646):1063–1066. doi: 10.1016/S0140-6736(89)92456-2
   PubMedGoogle Scholar
• Lueck CJ, Trend P, Swash M. Cyclosporin in the management of polymyositis and dermatomyositis. J Neurol Neurosurg Psychiatry. 1991 Nov;54(11):1007–1008. doi: 10.1136/jnnp.54.11.1007
   PubMed Web of Science ®Google Scholar
• Zeller V, Cohen P, Prieur AM, et al. Cyclosporin a therapy in refractory juvenile dermatomyositis. Experience and longterm followup of 6 cases. J Rheumatol. 1996 Aug;23(8):1424–1427.
   PubMed Web of Science ®Google Scholar
• Vencovsky J, Jarosova K, Machacek S, et al. Cyclosporine a versus methotrexate in the treatment of polymyositis and dermatomyositis. Scand J Rheumatol. 2000;29(2):95–102. doi: 10.1080/030097400750001897
   PubMed Web of Science ®Google Scholar
• Ruperto N, Pistorio A, Oliveira S, et al. Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial. Lancet. 2016 Feb 13;387(10019):671–678. doi: 10.1016/S0140-6736(15)01021-1
   PubMed Web of Science ®Google Scholar
• Yamada A, Ohshima Y, Omata N, et al. Steroid-sparing effect of tacrolimus in a patient with juvenile dermatomyositis presenting poor bioavailability of cyclosporine a. Eur J Pediatr. 2004 Sep;163(9):561–562. doi: 10.1007/s00431-004-1497-7
   PubMed Web of Science ®Google Scholar
• Martín Nalda A, Modesto Caballero C, Arnal Guimeral C, et al. Efficacy of tacrolimus (FK-506) in the treatment of recalcitrant juvenile dermatomyositis: study of 6 cases. Med Clin. 2006 Nov 11;127(18):697–701. doi: 10.1016/S0025-7753(06)72367-3
   PubMed Web of Science ®Google Scholar
• Matsubara S, Kondo K, Sugaya K, et al. Effects of tacrolimus on dermatomyositis and polymyositis: a prospective, open, non-randomized study of nine patients and a review of the literature. Clin Rheumatol. 2012 Oct;31(10):1493–1498. doi: 10.1007/s10067-012-2044-y
   PubMed Web of Science ®Google Scholar
• Kurita T, Yasuda S, Oba K, et al. The efficacy of tacrolimus in patients with interstitial lung diseases complicated with polymyositis or dermatomyositis. Rheumatology (Oxford). 2015 Jan;54(1):39–44. doi: 10.1093/rheumatology/keu166
   PubMed Web of Science ®Google Scholar
• Ueno KI, Shimojima Y, Kishida D, et al. Advantage of administering tacrolimus for improving prognosis of patients with polymyositis and dermatomyositis. Int J Of Rheum Dis. 2016 Dec;19(12):1322–1330. doi: 10.1111/1756-185X.12931
   PubMed Web of Science ®Google Scholar
• Takada K, Katada Y, Ito S, et al. Impact of adding tacrolimus to initial treatment of interstitial pneumonitis in polymyositis/dermatomyositis: a single-arm clinical trial. Rheumatology (Oxford). 2020 May 1;59(5):1084–1093. doi: 10.1093/rheumatology/kez394
   PubMed Web of Science ®Google Scholar
• Fujisawa T, Hozumi H, Kamiya Y, et al. Prednisolone and tacrolimus versus prednisolone and cyclosporin a to treat polymyositis/dermatomyositis-associated ILD: a randomized, open-label trial. Respirology. 2021 Apr;26(4):370–377. doi: 10.1111/resp.13978
   PubMed Web of Science ®Google Scholar
• Kuwana M, Wakasugi N, Furuya T, et al. Tacrolimus in patients with interstitial pneumonia associated with polymyositis or dermatomyositis: interim report of postmarketing surveillance in Japan. J Rheumatol. 2022 Jul;49(7):707–718. doi: 10.3899/jrheum.210322
   PubMed Web of Science ®Google Scholar
• Hassan J, van der Net JJ, van Royen-Kerkhof A. Treatment of refractory juvenile dermatomyositis with tacrolimus. Clin Rheumatol. 2008 Nov;27(11):1469–1471. doi: 10.1007/s10067-008-0973-2
   PubMed Web of Science ®Google Scholar
• Pyzik M, Rath T, Lencer WI, et al. FcRn: the architect behind the immune and nonimmune functions of IgG and albumin. J Immunol. 2015 May 15;194(10):4595–4603. doi: 10.4049/jimmunol.1403014
   PubMed Web of Science ®Google Scholar
• Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med. 1993 Dec 30;329(27):1993–2000. doi: 10.1056/NEJM199312303292704
   PubMed Web of Science ®Google Scholar
• Aggarwal R, Charles-Schoeman C, Schessl J, et al. Trial of intravenous immune globulin in dermatomyositis. N Engl J Med. 2022 Oct 6;387(14):1264–1278. doi: 10.1056/NEJMoa2117912
   PubMed Web of Science ®Google Scholar
• Cherin P, Belizna C, Cartry O, et al. Long-term subcutaneous immunoglobulin use in inflammatory myopathies: a retrospective review of 19 cases. Autoimmun Rev. 2016 Mar;15(3):281–286. doi: 10.1016/j.autrev.2015.12.003
   PubMed Web of Science ®Google Scholar
• Danieli MG, Verga JU, Mezzanotte C, et al. Replacement and immunomodulatory activities of 20% subcutaneous immunoglobulin treatment: a single-center retrospective study in autoimmune myositis and CVID patients. Front Immunol. 2021;12:805705. doi: 10.3389/fimmu.2021.805705
   PubMed Web of Science ®Google Scholar
• Speth F, Haas JP, Hinze CH. Treatment with high-dose recombinant human hyaluronidase-facilitated subcutaneous immune globulins in patients with juvenile dermatomyositis who are intolerant to intravenous immune globulins: a report of 5 cases. Pediatr Rheumatol Online J. 2016 Sep 13;14(1):52.
   PubMedGoogle Scholar
• Thompson C, Piguet V, Choy E. The pathogenesis of dermatomyositis. Br J Dermatol. 2018;179(6):1256–1262. doi: 10.1111/bjd.15607
   PubMed Web of Science ®Google Scholar
• BADER-MEUNIER B, DECALUWE H, BARNERIAS C, et al. Safety and efficacy of rituximab in severe juvenile dermatomyositis: results from 9 patients from the French autoimmunity and rituximab registry. J Rheumatol. 2011;38(7):1436–1440. doi: 10.3899/jrheum.101321
   PubMed Web of Science ®Google Scholar
• Levine TD. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis & Rheumatism. 2005;52(2):601–607. doi: 10.1002/art.20849
   PubMed Web of Science ®Google Scholar
• Rios Fernández R, Callejas Rubio JL, Sánchez Cano D, et al. Rituximab in the treatment of dermatomyositis and other inflammatory myopathies. A report of 4 cases and review of the literature. Clin Exp Rheumatol. 2009 Nov;27(6):1009–1016.
   PubMed Web of Science ®Google Scholar
• Dinh HV, McCormack C, Hall S, et al. Rituximab for the treatment of the skin manifestations of dermatomyositis: a report of 3 cases. J Am Acad Dermatol. 2007 Jan 01;56(1):148–153. doi: 10.1016/j.jaad.2006.05.068
   PubMed Web of Science ®Google Scholar
• Oddis CV, Reed AM, Aggarwal R, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum. 2013 Feb;65(2):314–324. doi: 10.1002/art.37754
   PubMed Web of Science ®Google Scholar
• Kuye IO, Smith GP. The use of rituximab in the management of refractory dermatomyositis. J Drugs Dermatol. 2017 Feb 1;16(2):162–166.
   PubMed Web of Science ®Google Scholar
• Aggarwal R, Loganathan P, Koontz D, et al. Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab. Rheumatology (Oxford). 2017 Feb;56(2):247–254. doi: 10.1093/rheumatology/kew396
   PubMed Web of Science ®Google Scholar
• Banerjee S, Biehl A, Gadina M, et al. JAK-STAT signaling as a target for inflammatory and autoimmune diseases: Current and future prospects. Drugs. 2017 Apr;77(5):521–546. doi: 10.1007/s40265-017-0701-9
   PubMed Web of Science ®Google Scholar
• Hu X, Li J, Fu M, et al. The JAK/STAT signaling pathway: from bench to clinic. Signal Transduct Ther. 2021 Nov 26;6(1):402. doi: 10.1038/s41392-021-00791-1
   PubMed Web of Science ®Google Scholar
• Paik JJ, Lubin G, Gromatzky A, et al. Use of Janus kinase inhibitors in dermatomyositis: a systematic literature review. Clin Exp Rheumatol. 2023 Mar;41(2):348–358. doi: 10.55563/clinexprheumatol/hxin6o
   PubMed Web of Science ®Google Scholar
• Kurtzman DJB, Wright NA, Lin J, et al. Tofacitinib citrate for refractory cutaneous dermatomyositis: an alternative treatment. JAMA Dermatol. 2016;152(8):944–945. doi: 10.1001/jamadermatol.2016.0866
   PubMed Web of Science ®Google Scholar
• Paik JJ, Casciola-Rosen L, Shin JY, et al. Study of tofacitinib in refractory dermatomyositis: an open-label pilot study of Ten patients. Arthritis & rheumat. 2021 May;73(5):858–865. doi: 10.1002/art.41602
   PubMed Web of Science ®Google Scholar
• Sozeri B, Demir F. A striking treatment option for recalcitrant calcinosis in juvenile dermatomyositis: tofacitinib citrate. Rheumatology (Oxford). 2020 Dec 1;59(12):e140–e141.
   PubMed Web of Science ®Google Scholar
• Zhao Q, Zhu Z, Fu Q, et al. Baricitinib for the treatment of cutaneous dermatomyositis: a prospective, open-label study. J Am Acad Dermatol. 2022 Dec 01;87(6):1374–1376. doi: 10.1016/j.jaad.2022.08.025
   PubMed Web of Science ®Google Scholar
• Kim H, Dill S, O’Brien M, et al. Janus kinase (JAK) inhibition with baricitinib in refractory juvenile dermatomyositis. Ann Rheum Dis. 2021 Mar;80(3):406–408. doi: 10.1136/annrheumdis-2020-218690
   PubMed Web of Science ®Google Scholar
• Wang Z, Zheng Q, Xuan W, et al. Short-term effectiveness of baricitinib in children with refractory and/or severe juvenile dermatomyositis. Front Pediatr. 2022;10:962585. doi: 10.3389/fped.2022.962585
   PubMed Web of Science ®Google Scholar
• Landon-Cardinal O, Guillaume-Jugnot P, Toquet S, et al. JAK inhibitors for the treatment of adult dermatomyositis: a pilot study. J Am Acad Dermatol. 2023 Apr;88(4):924–926. doi: 10.1016/j.jaad.2022.10.055
   PubMed Web of Science ®Google Scholar
• Hornung T, Janzen V, Heidgen F-J, et al. Remission of recalcitrant dermatomyositis treated with Ruxolitinib. N Engl J Med. 2014;371(26):2537–2538. doi: 10.1056/NEJMc1412997
   PubMed Web of Science ®Google Scholar
• Ladislau L, Suárez-Calvet X, Toquet S, et al. JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis. Brain. 2018;141(6):1609–1621. doi: 10.1093/brain/awy105
   PubMed Web of Science ®Google Scholar
• Woo TY, Callen JP, Voorhees JJ, et al. Cutaneous lesions of dermatomyositis are improved by hydroxychloroquine. J Am Acad Dermatol. 1984 Apr;10(4):592–600. doi: 10.1016/S0190-9622(84)80263-7
   PubMed Web of Science ®Google Scholar
• Wolstencroft PW, Casciola-Rosen L, Fiorentino DF. Association between autoantibody phenotype and cutaneous adverse reactions to hydroxychloroquine in dermatomyositis. JAMA Dermatol. 2018 Oct 1;154(10):1199–1203.
   PubMed Web of Science ®Google Scholar
• Pelle MT, Callen JP. Adverse cutaneous reactions to hydroxychloroquine are more common in patients with dermatomyositis than in patients with cutaneous lupus erythematosus. Arch Dermatol. 2002 Sep;138(9):1231–1233. discussion 1233. doi: 10.1001/archderm.138.9.1231
   PubMedGoogle Scholar
• Aggarwal R, Marder G, Koontz DC, et al. Efficacy and safety of adrenocorticotropic hormone gel in refractory dermatomyositis and polymyositis. Ann Rheum Dis. 2018 May;77(5):720–727. doi: 10.1136/annrheumdis-2017-212047
   PubMed Web of Science ®Google Scholar
• Linsley PS, Brady W, Urnes M, et al. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med. 1991;174(3):561–569. doi: 10.1084/jem.174.3.561
   PubMed Web of Science ®Google Scholar
• Tjärnlund A, Tang Q, Wick C, et al. Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase IIb treatment delayed-start trial. Ann Rheumatic Dis. 2018;77(1):55–62. doi: 10.1136/annrheumdis-2017-211751
   PubMed Web of Science ®Google Scholar
• Arabshahi B, Silverman RA, Jones OY, et al. Abatacept and sodium thiosulfate for treatment of recalcitrant juvenile dermatomyositis complicated by ulceration and Calcinosis. J Paediatr. 2012 Mar 01;160(3):520–522. doi: 10.1016/j.jpeds.2011.11.057
   PubMed Web of Science ®Google Scholar
• Sukumaran S, Vijayan V. Abatacept in the treatment of juvenile dermatomyositis-associated calcifications in a 16-year-old girl. Case Rep Rheumatol. 2020;2020:4073879. doi: 10.1155/2020/4073879
   PubMedGoogle Scholar
• Rodziewicz M, Kiely P. The successful use of subcutaneous abatacept in refractory anti- human transcriptional intermediary factor 1-gamma dermatomyositis skin and oesphagopharyngeal disease. Rheumatology. 2018;57(10):1866–1867. doi: 10.1093/rheumatology/key146
   PubMedGoogle Scholar
• Curiel RV, Nguyen W, Mamyrova G, et al. Improvement in disease activity in refractory juvenile dermatomyositis following Abatacept therapy. Arthritis & Rheumat. 2023;75(7):1229–1237. doi: 10.1002/art.42450
   PubMed Web of Science ®Google Scholar
• Efthimiou P, Schwartzman S, Kagen LJ. Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients. Ann Rheum Dis. 2006 Sep;65(9):1233–1236. doi: 10.1136/ard.2005.048744
   PubMed Web of Science ®Google Scholar
• Iannone F, Scioscia C, Falappone PC, et al. Use of etanercept in the treatment of dermatomyositis: a case series. J Rheumatol. 2006 Sep;33(9):1802–1804.
   PubMed Web of Science ®Google Scholar
• Dastmalchi M, Grundtman C, Alexanderson H, et al. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis. 2008 Dec;67(12):1670–1677. doi: 10.1136/ard.2007.077974
   PubMed Web of Science ®Google Scholar
• Hengstman GJ, De Bleecker JL, Feist E, et al. Open-label trial of anti-TNF-alpha in dermato- and polymyositis treated concomitantly with methotrexate. Eur Neurol. 2008;59(3–4):159–163. doi: 10.1159/000114036
   PubMed Web of Science ®Google Scholar
• Rouster-Stevens KA, Ferguson L, Morgan G, et al. Pilot study of etanercept in patients with refractory juvenile dermatomyositis. Arthritis Care Res (Hoboken). 2014 May;66(5):783–787. doi: 10.1002/acr.22198
   PubMed Web of Science ®Google Scholar
• Schiffenbauer A, Garg M, Castro C, et al. A randomized, double-blind, placebo-controlled trial of infliximab in refractory polymyositis and dermatomyositis. Semin Arthritis Rheum. 2018 Jun;47(6):858–864. doi: 10.1016/j.semarthrit.2017.10.010
   PubMed Web of Science ®Google Scholar
• A randomized, pilot trial of etanercept in dermatomyositis. Ann Neurol. 2011 Sep;70(3):427–436. doi: 10.1002/ana.22477
   PubMed Web of Science ®Google Scholar
• Konohana A, Kawashima J. Successful treatment of dermatomyositis with dapsone. Clin Exp Dermatol. 1994 Jul;19(4):367. doi: 10.1111/j.1365-2230.1994.tb01220.x
   PubMed Web of Science ®Google Scholar
• Ishibuchi H, Motegi S, Amano H, et al. Successful treatment with dapsone for skin lesions of amyopathic dermatomyositis. J Dermatol. 2015 Oct;42(10):1019–1021. doi: 10.1111/1346-8138.12999
   PubMed Web of Science ®Google Scholar
• Cohen JB. Cutaneous involvement of dermatomyositis can respond to dapsone therapy. Int J Dermatol. 2002 Mar;41(3):182–184. doi: 10.1046/j.1365-4362.2002.01409.x
   PubMed Web of Science ®Google Scholar
• Bitar C, Ninh T, Brag K, et al. Apremilast in recalcitrant cutaneous dermatomyositis: a nonrandomized controlled trial. JAMA Dermatol. 2022 Dec 1;158(12):1357–1366. doi: 10.1001/jamadermatol.2022.3917
   PubMed Web of Science ®Google Scholar
• Tran T, Chen A, Worswick S. Successful treatment of dermatomyositis with low-dose naltrexone. Dermatol Ther. 2018 Nov;31(6):e12720. doi: 10.1111/dth.12720
   PubMed Web of Science ®Google Scholar
• Manudhane AP, Schrom KP, Ezaldein HH, et al. Low-dose naltrexone: a unique treatment for amyopathic dermatomyositis. Dermatol Online J. 2019 Jun 15;25(6): doi: 10.5070/D3256044451
   PubMedGoogle Scholar
• Boswell JS, Costner MI. Leflunomide as adjuvant treatment of dermatomyositis. J Am Acad Dermatol. 2008 Mar;58(3):403–406. doi: 10.1016/j.jaad.2007.08.014
   PubMed Web of Science ®Google Scholar
• de Souza RC, de Souza FHC, Miossi R, et al. Efficacy and safety of leflunomide as an adjuvant drug in refractory dermatomyositis with primarily cutaneous activity. Clin Exp Rheumatol. 2017 Nov;35(6):1011–1013.
   PubMed Web of Science ®Google Scholar
• Zong M, Dorph C, Dastmalchi M, et al. Anakinra treatment in patients with refractory inflammatory myopathies and possible predictive response biomarkers: a mechanistic study with 12 months follow-up. Ann Rheum Dis. 2014 May;73(5):913–920. doi: 10.1136/annrheumdis-2012-202857
   PubMed Web of Science ®Google Scholar
• Groh M, Rogowska K, Monsarrat O, et al. Interleukin-1 receptor antagonist for refractory anti-MDA5 clinically amyopathic dermatomyopathy. Clin Exp Rheumatol. 2015 Nov;33(6):904–905.
   PubMed Web of Science ®Google Scholar
• Werth VP, Hejazi E, Pena SM, et al. Safety and efficacy of Lenabasum, a cannabinoid receptor type 2 agonist, in patients with dermatomyositis with refractory skin disease: a randomized clinical trial. J Invest Dermatol. 2022 Oct;142(10):2651–2659.e1. doi: 10.1016/j.jid.2022.03.029
   PubMed Web of Science ®Google Scholar
• Corbus Pharmaceuticals Announces Topline results from DETERMINE phase 3 study of Lenabasum for treatment of Dermatomyositis [Internet]. 2021. Available from: https://www.globenewswire.com/news-release/2021/06/24/2252567/0/en/Corbus-Pharmaceuticals-Announces-Topline-Results-from-DETERMINE-Phase-3-Study-of-Lenabasum-for-Treatment-of-Dermatomyositis.html
   Google Scholar
• Narazaki M, Hagihara K, Shima Y, et al. Therapeutic effect of tocilizumab on two patients with polymyositis. Rheumatology (Oxford). 2011 Jul;50(7):1344–1346. doi: 10.1093/rheumatology/ker152
   PubMed Web of Science ®Google Scholar
• Oddis CV, Rockette HE, Zhu L, et al. Randomized trial of Tocilizumab in the treatment of refractory adult polymyositis and Dermatomyositis. ACR Open Rheumatol. 2022 Nov;4(11):983–990. doi: 10.1002/acr2.11493
   PubMedGoogle Scholar
• Pinal-Fernandez I, Quintana A, Milisenda JC, et al. Transcriptomic profiling reveals distinct subsets of immune checkpoint inhibitor induced myositis. Ann Rheum Dis. 2023 Feb 17;82(6):829–836. doi: 10.1136/ard-2022-223792
   PubMed Web of Science ®Google Scholar
• Guerra NL, Matas-Garcia A, Serra-Garcia L, et al. Dermatomyositis unleashed by immune checkpoint inhibitors. Three additional cases and a review of the literature. Autoimmun Rev. 2023 Jun 13;22(8):103375. doi: 10.1016/j.autrev.2023.103375
   PubMed Web of Science ®Google Scholar
• Cagnoli M, Marchesoni A, Tosi S. Combined steroid, methotrexate and chlorambucil therapy for steroid-resistant dermatomyositis. Clin Exp Rheumatol. 1991 Nov;9(6):658–659.
   PubMed Web of Science ®Google Scholar
• Sinoway PA, Callen JC. An effective corticosteroid-sparing agent for patients with recalcitrant dermatomyositis. Arthritis Rheum. 1993 Mar;36(3):319–324. doi: 10.1002/art.1780360305
   PubMedGoogle Scholar
• Nadiminti U, Arbiser JL. Rapamycin (sirolimus) as a steroid-sparing agent in dermatomyositis. J Am Acad Dermatol. 2005 Feb;52(2 Suppl 1):17–19. doi: 10.1016/j.jaad.2004.05.044
   PubMed Web of Science ®Google Scholar
• Malek TR. The biology of Interleukin-2. Annu Rev Immunol. 2008;26(1):453–479. doi: 10.1146/annurev.immunol.26.021607.090357
   PubMed Web of Science ®Google Scholar
• Rosenzwajg M, Lorenzon R, Cacoub P, et al. Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial. Ann Rheumatic Dis. 2019;78(2):209–217. doi: 10.1136/annrheumdis-2018-214229
   PubMed Web of Science ®Google Scholar
• Zhang S-X, Wang J, Sun H-H, et al. Circulating regulatory T cells were absolutely decreased in dermatomyositis/polymyositis patients and restored by low-dose IL-2. Ann Rheumatic Dis. 2021;80(8):e130–e130. doi: 10.1136/annrheumdis-2019-216246
   PubMed Web of Science ®Google Scholar
• Pinal-Fernandez I, Kroodsma CT, Mammen AL. Successful treatment of refractory mechanic’s hands with ustekinumab in a patient with the antisynthetase syndrome. Rheumatology (Oxford). 2019 Jul 1;58(7):1307–1308.
   PubMed Web of Science ®Google Scholar
• Mackensen A, Müller F, Mougiakakos D, et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nature Med. 2022 Oct 01;28(10):2124–2132. doi: 10.1038/s41591-022-02017-5
   PubMed Web of Science ®Google Scholar
• Müller F, Boeltz S, Knitza J, et al. CD19-targeted CAR T cells in refractory antisynthetase syndrome. Lancet. 2023 Mar 11;401(10379):815–818. doi: 10.1016/S0140-6736(23)00023-5
   PubMed Web of Science ®Google Scholar
• Holzer U, van Royen-Kerkhof A, van der Torre P, et al. Successful autologous stem cell transplantation in two patients with juvenile dermatomyositis. Scand J Rheumatol. 2010;39(1):88–92. doi: 10.3109/03009740903096622
   PubMed Web of Science ®Google Scholar
• Kissel JT, Mendell JR, Rammohan KW. Microvascular deposition of complement membrane attack complex in dermatomyositis. N Engl J Med. 1986;314(6):329–334. doi: 10.1056/NEJM198602063140601
   PubMed Web of Science ®Google Scholar
• Lahoria R, Selcen D, Engel AG. Microvascular alterations and the role of complement in dermatomyositis. Brain. 2016;139(7):1891–1903. doi: 10.1093/brain/aww122
   PubMedGoogle Scholar
• FAGUER S, BELLIERE J, RIBES D. Complement C5-blocking agent in refractory dermatomyositis. J Rheumatol. 2018;45(12):1710–1711. doi: 10.3899/jrheum.180060
   PubMed Web of Science ®Google Scholar
• Mammen AL, Amato AA, Dimachkie MM, et al. Zilucoplan in immune-mediated necrotising myopathy: a phase 2, randomised, double-blind, placebo-controlled, multicentre trial. Lancet Rheumatol. 2023 Feb;5(2):e67–e76. doi: 10.1016/S2665-9913(23)00003-6
   PubMedGoogle Scholar
• Neelakantan S, Oemar B, Johnson K, et al. Safety, tolerability, and pharmacokinetics of PF-06823859, an anti–interferon β monoclonal antibody: a randomized, phase I, single- and multiple-ascending-dose study. Clin Pharmacol Drug Dev. 2021;10(3):307–316. doi: 10.1002/cpdd.887
   PubMed Web of Science ®Google Scholar
• Zhang C, Zhu H, Shao J, et al. Immunoproteasome-selective inhibitors: the future of autoimmune diseases? Future Med Chem. 2020;12(4):269–272. doi: 10.4155/fmc-2019-0299
   PubMed Web of Science ®Google Scholar
• Ah Kioon MD, Pierides M, Pannellini T, et al. Noncytotoxic inhibition of the immunoproteasome regulates human immune cells in vitro and suppresses cutaneous inflammation in the mouse. J Immunol. 2021;206(7):1631–1641. doi: 10.4049/jimmunol.2000951
   PubMed Web of Science ®Google Scholar
• Del Rio Oliva M, Kirk CJ, Groettrup M, et al. Effective therapy of polymyositis in mice via selective inhibition of the immunoproteasome. Eur J Immunol. 2022 Sep;52(9):1510–1522. doi: 10.1002/eji.202249851
   PubMed Web of Science ®Google Scholar
• Debrut L, Giannini M, Keime C, et al. OP0117 proteasome inhibition as a new treatment for dermatomyositis: results of a drug repurposing analysis based on the transcriptomic signature of patients’ perifascicular fibers validated in pre-clinical models. Ann Rheumatic Dis. 2023;82(Suppl 1):77–77.
   Google Scholar
• Ziade N, Aoude M, Hmamouchi I, et al. Global disparities in the treatment of idiopathic inflammatory myopathies: results from an international online survey study. Rheumatology (Oxford). 2023 May 25. doi: 10.1093/rheumatology/kead250
   Web of Science ®Google Scholar
• Danieli MG, Tonacci A, Paladini A, et al. A machine learning analysis to predict the response to intravenous and subcutaneous immunoglobulin in inflammatory myopathies. A proposal for a future multi-omics approach in autoimmune diseases. Autoimmun Rev. 2022 Jun;21(6):103105. doi: 10.1016/j.autrev.2022.103105
   PubMed Web of Science ®Google Scholar